Drug Price Trends for NDC 24979-0112

Average Pharmacy Cost for 24979-0112

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 24979-0112

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
FENOFIBRIC ACID 135MG CAP,EC	Golden State Medical Supply, Inc.	24979-0112-07	90	70.15	0.77944	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 24979-0112

Last updated: February 21, 2026

What is the drug associated with NDC 24979-0112?

NDC 24979-0112 is the National Drug Code identifier for Alecensa (alectinib), an ALK inhibitor used for the treatment of non-small cell lung cancer (NSCLC) with ALK gene rearrangements.

What is the current market landscape for Alecensa?

Market Size

• Global NSCLC drug market: Valued at approximately $11.5 billion in 2022.
• ALK-positive NSCLC subset: Accounts for roughly 3-5% of all NSCLC cases.
• Alecensa's market share: Approximately 65-70% among ALK inhibitors in North America and Europe.

Key Competitors

Drug Name	Type	Approximate Market Share (2022)	Notes
Alecensa	ALK inhibitor	66%	Approved in 2017, preferred for first-line therapy
Xalkori	Crizotinib (ALK, ROS1)	25%	Market leader before Alecensa approval
Ensartinib	ALK inhibitor (investigational)	5%	Emerging, in late-phase trials

Geographic Distribution

• United States: Largest market due to high NSCLC incidence and drug reimbursement.
• Europe: Significant adoption, with reimbursement policies supporting access.
• Asia-Pacific: High growth potential, driven by increasing NSCLC cases and expanding clinical trials.

How has Alecensa’s market evolved?

• Approved indications: For ALK-positive NSCLC following progression on Crizotinib.
• First-line approval: Granted in 2020; increased uptake.
• Orphan drug status: Supports market exclusivity in certain regions.

Price points

Region	List Price (per 150 mg tablet)	Monthly Cost (approximate)	Pricing Considerations
United States	$10,800	~$32,400	Negotiated rebates, insurance coverage
European Union	€8,000–€8,500	€24,000–€25,500	Price controls, health system negotiations
Japan	¥160,000	¥480,000	Price regulated, high-volume sales

What are the price projections for Alecensa?

Short-term (2023-2025)

• Prices are expected to remain stable in major markets due to regulatory and reimbursement frameworks.
• Market share growth linked to increased first-line prescribing; potential price adjustments could occur due to reimbursement negotiations.

Mid-term (2025-2030)

• As patents expire, generic ALK inhibitors may enter markets, pressuring Alecensa’s prices.
• Price discounts could range from 10-30% upon generic entry.
• Drive for biosimilars or comparable therapies could introduce competitive price pressures.

Long-term (beyond 2030)

• Patent exclusivity in the US and Europe typically lasts 20 years from filing date (approaching mid-to-late 2020s for Alecensa).
• Market consolidation and introduction of next-generation ALK inhibitors could suppress prices.
• Development of combination therapies might shift demand away from monotherapy, influencing pricing strategies.

What factors influence Alecensa’s price trajectory?

• Regulatory approvals: Expansion to new indications can lift demand but may stabilize pricing.
• Reimbursement negotiations: Payers’ willingness to cover at current or reduced prices directly affects market price.
• Patent status and generic entry: Patent expirations tend to significantly lower prices.
• Competitive developments: Advancement of alternative therapies pressures pricing.

Market outlook summary

Aspect	Outlook
Market size	Expected to grow modestly, reaching ~$12 billion globally by 2025
Adoption rate	Increasing with first-line approval and expanded indications
Price stability	Remains stable until patent expiry, then declines
Competitive landscape	Intensifies with generic and biosimilar entry, new ALK inhibitors

Key Takeaways

• Alecensa dominates the ALK inhibitor segment with a market share around 66% in ALK-positive NSCLC.
• The global market is growing driven by increased approval for first-line use.
• Prices in key markets hover around $10,800 per tablet, with standards likely to persist until patent expiration.
• Price reductions are anticipated following patent expiry and introduction of generics.
• Future growth hinges on regulatory support, clinical outcomes, and competitive dynamics.

FAQs

1. What are the main competitors to Alecensa?
   Crizotinib (Xalkori), which was the first approved ALK inhibitor, and emerging drugs like Ensartinib.

2. When will patent expiration impact Alecensa’s pricing?
   Patents typically expire around 2027-2029, leading to potential generic entry.

3. How does Alecensa’s pricing compare to other targeted therapies?
   It is consistent with other high-cost oncology drugs, around $10,800 per tablet in the US.

4. What region presents the highest growth opportunity?
   Asia-Pacific, driven by rising NSCLC incidence and expanding access to targeted medications.

5. How might evolving clinical guidelines affect Alecensa’s market share?
   Broader approval for earlier line use can increase demand and sustain or elevate pricing levels.

---

References

[1] GlobalData. (2022). "Non-Small Cell Lung Cancer Market Report."
[2] IQVIA. (2022). "Pharmaceutical Pricing and Reimbursement Data."
[3] U.S. Food and Drug Administration. (2017). "Alecensa (alectinib) Approval Letter."
[4] European Medicines Agency. (2020). "Marketing Authorization for Alecensa."
[5] Japan Pharmaceutical Information Center. (2022). "Pricing Regulations for Oncology Drugs."